Download presentation
Presentation is loading. Please wait.
Published byΝύξ Μπουκουβαλαίοι Modified over 5 years ago
1
Half-life of removal from subcutaneous administration site after subcutaneous administration of fluorescence-labeled VEGF-C156S, ovalbumin (OVA), bovine serum albumin (BSA), and bevacizumab in mice (data from Wu et al., 2012). Half-life of removal from subcutaneous administration site after subcutaneous administration of fluorescence-labeled VEGF-C156S, ovalbumin (OVA), bovine serum albumin (BSA), and bevacizumab in mice (data from Wu et al., 2012). Wolfgang F. Richter, and Björn Jacobsen Drug Metab Dispos 2014;42: Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.